Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission

Naranie Shanmuganathan; Jodi A Braley; Agnes S M Yong; Devendra K Hiwase; David T Yeung; David M Ross; Timothy P Hughes; Susan Branford

doi:10.1182/blood.2019000120

Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission

Blood. 2019 Jul 4;134(1):85-89. doi: 10.1182/blood.2019000120. Epub 2019 Apr 9.

Authors

Naranie Shanmuganathan^{1

2

3

4

5

6

7}, Jodi A Braley⁷, Agnes S M Yong^{4

6}, Devendra K Hiwase^{1

2

4

6}, David T Yeung^{1

2

4

5

6}, David M Ross^{1

2

3

4

6

8}, Timothy P Hughes^{1

2

4

5

6}, Susan Branford^{3

5

6

7

9}

Affiliations

¹ Department of Haematology, Royal Adelaide Hospital, Adelaide, SA, Australia.
² Department of Haematology and.
³ Centre for Cancer Biology, SA Pathology, Adelaide, SA, Australia.
⁴ Cancer Theme, South Australian Health & Medical Research Institute, Adelaide, SA, Australia.
⁵ School of Pharmacy and Medical Science, University of South Australia, Adelaide, SA, Australia.
⁶ School of Medicine, University of Adelaide, Adelaide, SA, Australia.
⁷ Department of Genetics and Molecular Pathology, SA Pathology, Adelaide, SA, Australia.
⁸ Department of Haematology, Flinders University and Medical Centre, Adelaide, SA, Australia; and.
⁹ School of Biological Sciences, University of Adelaide, Adelaide, SA, Australia.

PMID: 30967368
DOI: 10.1182/blood.2019000120

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Algorithms*
Antineoplastic Agents / therapeutic use
Fusion Proteins, bcr-abl / analysis*
Fusion Proteins, bcr-abl / genetics
Genetic Testing / standards*
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
Neoplasm Recurrence, Local / diagnosis*
Protein Kinase Inhibitors / therapeutic use
Remission Induction

Substances

Antineoplastic Agents
Protein Kinase Inhibitors
Fusion Proteins, bcr-abl